Molecular targeted agents--where we are and where we are going

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• In 2012, the U.S. Food and Drug Administration (FDA) approved 23 new cancer medicines or expanded indications for existing drugs.
• Twelve of these approvals were new molecular entities (NMEs), representing novel chemical or biological drugs for oncologic use.
• Ten NMEs were classified as molecular targeted agents, including four anti-angiogenesis agents and two Bcr-Abl pathway inhibitors.

Discussion:

• The approval of targeted agents like bevacizumab and imatinib highlights progress in cancer therapy.
• Key questions remain regarding the sufficiency of current treatments for diverse cancer types.
• The origin of future cancer drug innovations and optimal R&D investment strategies require consideration.

Key Insights:

• The FDA approved 10 molecular targeted agents as NMEs in 2012, advancing cancer treatment options.
• Targeted therapies are increasingly important, with specific agents addressing pathways like angiogenesis and Bcr-Abl.
• Despite advancements, challenges persist in providing comprehensive treatment coverage for all cancer types.

Outlook:

• Future cancer drug development should focus on addressing unmet needs and exploring novel research areas.
• Investment in R&D is crucial for continued improvement in cancer treatment and management.
• Special attention is needed for tumor types prevalent in specific regions, such as China, to improve global cancer care.